Bronchopulmonary dysplasia: Pathophysiology and potential anti-inflammatory therapies

Paediatr Respir Rev. 2019 Apr:30:34-41. doi: 10.1016/j.prrv.2018.07.007. Epub 2018 Jul 29.

Abstract

Inflammation of the preterm lungs is key to the pathogenesis of bronchopulmonary dysplasia (BPD), whether it arises as a consequence of intrauterine inflammation or postnatal respiratory management. This review explores steroidal and non-steroidal therapies for reducing neonatal pulmonary inflammation, aimed at treating or preventing BPD.

Keywords: Bronchopulmonary dysplasia; Chorioamnionitis; Dexamethasone; Glucocorticoid; Inflammation; Pulmonary.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Bronchopulmonary Dysplasia / drug therapy*
  • Bronchopulmonary Dysplasia / immunology*
  • Bronchopulmonary Dysplasia / physiopathology
  • Chorioamnionitis / immunology
  • Dexamethasone / therapeutic use
  • Female
  • Fetal Organ Maturity
  • Glucocorticoids / therapeutic use*
  • Humans
  • Infant, Extremely Premature
  • Infant, Newborn
  • Infant, Premature
  • Inflammation
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors
  • Neonatal Sepsis / immunology
  • Pentoxifylline / therapeutic use
  • Pregnancy
  • Prenatal Care

Substances

  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Interleukin 1 Receptor Antagonist Protein
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Dexamethasone
  • Pentoxifylline